^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + ceralasertib (AZD6738) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
13P - Synergistic activity of PARP inhibitor and ATR inhibitor in melanoma cell lines may depend on BRAF-V600 mutation status
Published date:
09/14/2020
Excerpt:
Two BRAF-V600 mutant melanoma cell lines (A375 and SAN) and their in-vitro vemurafenib and cobimetinib resistant derivatives (A375-VRCR and SAN-VRCR, respectively), two NRAS mutant melanoma cell lines (SK-MEL-2 and WM1366) and one BRAF/NRAS wild type melanoma cell line (MeWo) have been treated with AZD6738, olaparib and their combination. MTT assays have shown that all four BRAF-V600 mutant cell lines are equally sensitive to AZD6738 (IC50: 1-1,5 μM), independently from acquired in-vitro resistance to vemurafenib and cobimetinib. Combination of AZD6738 and olaparib has shown drug synergism in all these four cell lines.
